Medication info
Citrica Capsule 75 mg (Pregabalin)

Citrica Capsule 75 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
HLB Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part, containing a powder that is white to light yellow.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201902046 · Approved 2019.04.04 · Insurance code 647303740

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies were also conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: Supplemental dose refers to a dose administered once in addition to the regular dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
HLB Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in patients with epilepsy, effective whether or not there are secondary general symptoms. It helps in the treatment of fibromyalgia, contributing to the relief of pain and improvement of quality of life. In summary, this drug is used for the treatment of peripheral and central neuropathic pain, adjunctive therapy for partial seizures in epilepsy, and for the treatment of fibromyalgia.

Dosage and Administration

Adult dosage

This medicine is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies were also conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: Supplemental dose refers to a dose administered once in addition to the regular dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years or older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so any mood changes or unusual behavior during use should be reported immediately to healthcare professionals. Patients with hypersensitivity to this medication or with genetic issues such as lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may complicate blood sugar control. In case of allergic reactions such as angioedema, the medication should be stopped immediately. Elderly patients are at risk of falling due to dizziness or drowsiness, so caution is required during the initial dosing. Visual disturbances or changes in vision may occur, and if symptoms persist, consultation with healthcare professionals is needed. Sudden withdrawal symptoms may occur after stopping the medication, so do not stop taking it abruptly. As there is a risk of drug abuse, patients with a history of substance abuse should be particularly careful. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should be cautious about the possibility of heart failure. When taken with opioid analgesics, the risk of central nervous system depression increases, so caution is advised. Patients with respiratory diseases, kidney disorders, or the elderly may be at risk of severe respiratory depression and may require dosage adjustments. Pregnant women should avoid taking this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or the medication as it may be passed into breast milk. Caution is needed after taking the medication when driving or operating machinery due to the risk of dizziness and drowsiness. Severe skin reactions may occur rarely, so if skin rash or blisters develop, stop taking the medication immediately and consult healthcare professionals. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment such as dialysis may be necessary.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial edema
  • periorbital edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 204 more
  • loss of consciousness
  • confusion
  • psychiatric disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like symptoms
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination disturbances
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex reduction
  • movement abnormalities
  • psychomotor hyperactivity
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing disability
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photopsia
  • dry eyes
  • conjunctival swelling
  • reduced vision
  • ocular pain
  • eye fatigue
  • increased lacrimation
  • ocular irritation
  • mydriasis
  • vibratory sensations
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hyperesthesia
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • reduced platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • reduced white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • lingual swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • affective disorders
  • drowsiness
  • confusion state
  • depression
  • agitation
  • restlessness
  • exacerbation of convulsions
  • gastrointestinal disturbances
  • tinnitus
  • sleep disorders
  • skin disease
  • increased BUN
  • bloody stool
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container as it may be sensitive to air or moisture. It is best to keep the storage temperature between 15 and 30 degrees Celsius to maintain the drug's efficacy and safety.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part, containing a powder that is white to light yellow.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.